tbuckley/cabot-search huggingface dataset:
Estimated Internal and External Radiation Exposure of Caregivers of Patients With Pediatric Neuroblastoma Undergoing 131I Metaiodobenzylguanidine Therapy
Authors: Sangwon Han, Seon Hee Yoo, Kyung-Nam Koh, Jong Jin Lee
Journal: Clinical Nuclear Medicine (2017)

Current recommendations suggest that family members should participate in the care of children receiving in-hospital I metaiodobenzylguanidine (MIBG) therapy for neuroblastoma. The present study aimed to measure the external radiation exposure and estimate the internal radiation exposure of caregivers during the hospital stay for I MIBG therapy.Caregivers received radiation safety instructions and a potassium iodide solution for thyroid blockade before patient admission. External radiation exposure was determined using a personal pocket dosimeter. Serial 24-hour urine samples were collected from caregivers during the hospital stay. Estimated internal radiation exposure was calculated based on the urine activity.Twelve cases (mean age, 6.2 ± 3.5 years; range, 2-13 years) were enrolled. The mean administered activity was 233.3 ± 74.9 (range, 150.0-350.0) mCi. The mean external radiation dose was 5.8 ± 7.2 (range, 0.8-19.9) mSv. Caregivers of children older than 4 years had significantly less external radiation exposure than those of children younger than 4 years (1.9 ± 1.0 vs 16.4 ± 5.0 mSv; P = 0.012). The mean estimated internal radiation dose was 11.3 ± 10.2 (range, 1.0-29.8) μSv.Caregivers receive both external and internal radiation exposure while providing in-hospital care to children receiving I MIBG therapy for neuroblastoma. However, the internal radiation exposure was negligible compared with the external radiation exposure.
Half of women experience “red flag” event during childbirth, warns report
Authors: Jacqui Wise
Journal: BMJ (2017)

Half of women in England and Wales experience at least one “red flag” event during childbirth as a result of dangerously low staffing levels, a report has warned.

Support Overdue: Women’s Experiences of Maternity Services 2017 ,1 a report from the National Federation of Women’s Institutes and the National Childbirth Trust, is based on an online survey of 2493 women who gave birth over the past three years in England and Wales. The findings suggest that little progress has been made since the publication of a previous report in 2013.2

The National Institute for Health and Care Excellence (NICE) defines red flag events as indicators of dangerously low …
MiR-29b Counteracts Aberrant HDAC4 Expression and Enhances Vorinostat Activity in Multiple Myeloma
Authors: Nicola Amodio, Marzia Leotta, Anna Maria Gullà, Lavinia Raimondi, Eugenio Morelli, Maria Angelica Stamato, Teresa Calimeri, Maria Teresa Di Martino, Marco Rossi, Emanuela Leone, Antonino Neri, Pierosandro Tagliaferri, Pierfrancesco Tassone
Journal: Blood (2014)
Restricted Oligo-Clonal Usage of Monoclonal Immunoglobulin λ Light Chain Germline in POEMS Syndrome.
Authors: Chiaki Nakaseko, Daijiro Abe, Masahiro Takeuchi, Yusuke Takeda, Hiroaki Tanaka, Kayo Oda, Chikako Ohwada, Shinichi Ozawa, Emiko Sakaida, Naomi Shimizu, Shinichi Masuda, Ryuko Cho, Miki Nishimura, Yasushi Saito, Sonoko Misawa, Satoshi Kuwabara
Journal: Blood (2007)
New Criteria To Identify Risk of Progression in Monoclonal Gammopathy of Uncertain Significance: Multiparametric Flow Cytometry Analysis of Bone Marrow Plasma Cells.
Authors: Ernesto Perez-Persona, María-Belén Vidriales, Gema Mateo, Ramón Garcia Sanz, Marivi Mateos, Alfonso Garcia de Coca, Josefina Galende, Guillermo Martin-Nunez, Jose M. Alonso, Natalia Heras, Jose M. Hernandez, Alejandro Martin, Consuelo Lopez-Berges, Alberto Orfao, J.F. San Miguel
Journal: Blood (2006)
The Role of Helicobacter Pylori in Japanese Children with Chronic Idiopathic Thrombocytopenic Purpura
Authors: Hisaya Nakadate, Jun-Ichi Kitazawa, Yasuo Horikoshi, Masayuki Nagasawa, Masue Imaizumi, Naoaki Kobayashi, Masao Kobayashi, Yukihiro Takahashi, Kohji Fujisawa, Akira Shirahata, Fumio Bessho
Journal: Blood (2011)
Recombinant FVIIIFc-VWF-XTEN Demonstrates Significant Bioavailability Following Subcutaneous Administration in Hemophilia A Mice
Authors: Douglas Drager, Sue Patarroyo-White, Hoson Chao, Ayman Ismail, Jiayun Liu, Amy M Holthaus, Ekta Chhabra, John Kulman, Volker Schellenberger, Tongyao Liu, Robert Peters
Journal: Blood (2015)
A Pilot Study Evaluating the Safety and Efficacy of AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients with Advanced Hematological Malignancies.
Authors: Steven M. Devine, Jesper Bonde, David A. Hess, Terri M. Edwards, Daniel C. Link, Diane Sempek, Gary Calandra, Karin Badel, Jan A. Nolta, John F. DiPersio
Journal: Blood (2004)
Corrigendum to “Inflammation and frailty in the elderly: A systematic review and meta-analysis” [Ageing Res Rev. 31 (2016) 1–8]
Authors: Pinar Soysal, Brendon Stubbs, Paola Lucato, Claudio Luchini, Marco Solmi, Roberto Peluso, Giuseppe Sergi, Ahmet Turan Isik, Enzo Manzato, Stefania Maggi, Marcello Maggio, A. Matthew Prina, Theodore D. Cosco, Yu-Tzu Wu, Nicola Veronese
Journal: Ageing Research Reviews (2017)
Reversible Self-Assembly of Weibel-Palade Body-Like Tubules from Recombinant N-Terminal Domains of von Willebrand Factor.
Authors: Ren-Huai Huang, Ying Wang, Robyn Roth, Xiong Yu, Angie R. Purvis, John E. Heuser, Edward H. Egelman, J. Evan Sadler
Journal: Blood (2007)
Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Authors: Hagop M. Kantarjian, Dong-Wook Kim, Surapol Issaragrisil, Richard E Clark, Josy Reiffers, Franck E. Nicolini, Ricardo Pasquini, Matt Kalaycio, Timothy P. Hughes, Andreas Hochhaus, Charisse Kemp, Xiaolin Fan, Roger J. Waltzman, Giuseppe Saglio, Richard A. Larson
Journal: Blood (2012)
Darwin's Illness
Authors: S. Adler
Journal: BMJ (1965)

or had become depressed as a result of the demecolcine or the radiotherapy, or a combination of both.Further patients with this condition on treatment here by radio- therapy are having platelet counts under- taken, though formerly this was not routine practice during palliative radiotherapy at low daily doses.We would be interested in any comments on these findings, but would suggest that if demecolcine plus radiotherapy is undertaken for superior mediastinal obstruction careful check should be kept on platelets as well as white blood count.
A Novel 5bp Deletion Mutation in the Factor X (FX) Gene, Designated FX-Augusta, Causes Severe FX Deficiency Possibly by a Unique Mechanism Involving mRNAs that Lack Inframe Stop Codons.
Authors: Afshin Ameri, Deepa K. Machiah, Darlene Livingston, Thuy T. Tran, Cynthia Channell, Kristen L. Toren, Valerie Crenshaw, Tom Howard
Journal: Blood (2004)
A New ETV6-RUNX1 In Vivo Model Produces a Phenocopy of the Human Pb-ALL
Authors: Guillermo rodriguez-Hernandez, Julia Hauer, Alberto Martín-Lorenzo, Daniel Schaefer, Christoph Bartenhagen, Idoia Garcia-Ramirez, Franziska Auer, Ines Gonzalez-Herrero, Lucia Ruiz-Roca, Vera Okpanyi, Ute Fischer, Martin Dugas, Sanil Bhatia, Michael Gombert, Pina Krell, Cai Chen, Marta Garcia Suquia, Maria Rascon Trincado, Angel Garcia Sanchez, Oscar Blanco, Maria garcia Cenador, Francisco Garcia-criado, Cesar Cobaleda, Diego Alonso-Lopez, Javier de Las Rivas, Carolina vicente-Duenas, Isidro Sanchez-Gracia, Arndt Borkhardt
Journal: Blood (2015)
A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia
Authors: Michael Dennis, Nigel H. Russell, Nicki Panoskaltsis, Claire Jane Hemmaway, Donald Milligan, Richard E Clark, Robert K. Hills, Alan K Burnett
Journal: Blood (2014)
Final Analysis of the RO-CHOP Phase Ib/II Study: Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma (PTCL)
Authors: Jehan Dupuis, Franck Morschhauser, Herve Ghesquieres, Herve Tilly, Olivier Casasnovas, Sandy Amorim, Vincent Ribrag, Bertrand Coiffier
Journal: Blood (2014)
The Long-Lerm Follow-Up of Childhood Acute Lymphoblastic Leukemia Treated in China with Chemotherapy under Poor Coverage of Medical Insurance: A Single Center Experience.
Authors: Yongmin Tang, Hua Song, Shuwen Shi, Shilong Yang, Jian Wei, Weiqun Xu, Binhua Pan, Yinghu Chen, Lingyan Zhang, Fenying Zhao, Botao Ning, Xiaojun Xu
Journal: Blood (2005)
Cancer cachexia awareness, diagnosis, and treatment are lacking among oncology providers
Authors: Mary Kay Barton
Journal: CA A Cancer Journal for Clinicians (2017)

Key Points Cancer cachexia appears to be underrecognized and undertreated by oncology HCPs in a multinational study. Cancer cachexia is a poor prognostic indicator that can profoundly affect well‐being and the ability to tolerate cancer treatments. Early identification of and intervention for cancer cachexia are needed as well as more effective treatments.
Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant
Authors: Lan-Ping Xu, Song Jin, Shun-Qing Wang, Ling-Hui Xia, Hai Bai, Su-Jun Gao, Qi-Fa Liu, Jian-Min Wang, Xin Wang, Ming Jiang, Xi Zhang, De-Pei Wu, Xiao-Jun Huang
Journal: Journal of Hematology & Oncology (2017)

Haploidentical donor (HID) hematopoietic stem cell transplantation (HSCT) is an alternative treatment method for severe aplastic anemia (SAA) patients lacking suitable identical donors and those who are refractory to immunosuppressive therapy (IST). The current study evaluated the feasibility of upfront haploidentical HSCT in SAA patients. We conducted a multicenter study based on a registry database. One hundred fifty-eight SAA patients who underwent upfront transplantation between June 2012 and September 2015 were enrolled. Eighty-nine patients had haploidentical donors (HIDs), and 69 had matched related donors (MRDs) for HSCT. The median times for myeloid engraftment in the HID and MRD cohorts were 12 (range, 9–20) and 11 (range, 8–19) days, with a cumulative incidence of 97.8 and 97.1% (P = 0.528), respectively. HID recipients had an increased cumulative incidence of grades II–IV acute graft-versus-host disease (aGVHD) (30.3 vs. 1.5%, P < 0.001), grades III–IV aGVHD (10.1 vs. 1.5%, P = 0.026), and chronic GVHD (cGVHD) (30.6 vs. 4.4%, P < 0.001) at 1 year but similar extensive cGVHD (3.4 vs. 0%, P = 0.426). The three-year estimated overall survival (OS) rates were 86.1 and 91.3% (P = 0.358), while the three-year estimated failure-free survival (FFS) rates were 85.0 and 89.8% (P = 0.413) in the HID and MRD cohorts, respectively. In multivariate analysis, survival outcome for the entire population was significantly adversely associated with increased transfusions and poor performance status pre-SCT. We did not observe differences in primary engraftment and survival outcomes by donor type. Haploidentical SCT as upfront therapy was an effective and safe option for SAA patients, with favorable outcomes in experienced centers.
Relapse Patterns and Subsequent Outcomes of Patients Treated on the NCIC CTG HD.6 (ECOG JHD06) Randomized Trial Evaluating ABVD Alone in Patients with Limited Stage Hodgkin Lymphoma (HL).
Authors: David A. Macdonald, Mary K. Gospodarowicz, Woodrow A. Wells, Robert G. Pearcey, Joseph M. Connors, Jane N. Winter, Sandra J. Horning, Marina S. Djurfeldt, Keyue Ding, Lois E. Shepherd, Ralph M. Meyer
Journal: Blood (2005)
MAGE-A3 Inhibits p53 and Promotes Proliferation and Survival in Multiple Myeloma.
Authors: Hearn J. Cho, Anna Mei, Tricia Nardiello, Maurizio DiLiberto, Xiangao Huang, Jennifer E Amengual, Achim Jungbluth, Scott Ely, Ruben Niesvizky, David S Jayabalan, Lloyd Old, Selina Chen-Kiang
Journal: Blood (2009)
Facilitating the delivery of patient-centered cancer care: Insights from the Patient-Centered Outcomes Research Institute's (PCORI) cancer portfolio.
Authors: Neeraj K. Arora, Christopher Gayer, William Lawrence, Vadim Gershteyn, Kelly Dunham, Evelyn Whitlock, Steven Clauser
Journal: Journal of Clinical Oncology (2016)

e18234 Background: PCORI funds comparative clinical effectiveness research (CER) that aims to produce evidence-based information to help people make informed health care decisions and improve outcomes that matter to patients. Cancer studies form one of the largest disease-specific PCORI-funded portfolios to date. Methods: We conducted a systematic analysis of PCORI’s cancer portfolio. Results: As of October 2015, PCORI has funded 49 cancer projects totaling $131 million. Cancer studies account for 14% of PCORI’s dollar investment in CER and are focusing on breast, lung, prostate, colorectal, cervical, ovarian, pancreatic, and hematologic cancers. A majority of studies are randomized trials (n = 28, 57%; 71% of dollar investment). Forty seven percent (23/49) compare the real world effectiveness of two or more interventions against each other and the remaining mostly compare an active intervention with usual care. Four studies are part of PCORI’s large pragmatic clinical studies program accounting for 37% of our dollar investment in cancer. These studies include comparisons of cancer screening and surveillance protocols, approaches to radiation therapy, and protocols for managing the side-effects of chemotherapy. Each study in PCORI’s cancer portfolio addresses important decisional dilemmas faced by patients, families, and clinicians throughout the cancer continuum from prevention, screening, diagnosis, treatment, post-treatment survivorship, and end of life. Interventions compared to address these dilemmas range from clinical approaches such as different screening protocols and treatment options, to decision support tools and patient decision-aids, to different models of organizing the delivery of care. Conclusions: PCORI-funded cancer studies are rigorously evaluating the real world impact of a range of interventions aimed at optimizing the delivery of patient-centered care. Our analysis of the cancer portfolio will synthesize the evidence gaps addressed by our studies, highlight how PCORI studies complement research funded by NIH, and help inform future PCORI efforts to improve patient-centered outcomes for cancer patients and families.
Long-Term Overall and Event-Free Survival after RIC Allogeneic Transplantation in Acute Leukemias in a Single Centre - Impact of Age and Donor Type?
Authors: Sebastian Wittnebel, Philippe Lewalle, Sandra Michiels, Soumaya Anoun, Benjamin Bailly, Marie Vercruyssen, Julie Dallemagne, Sarah Buntinx, Phuong Huynh, Patrick Crombez, Marie France Jaivenois, Dominique Bron
Journal: Blood (2015)
Prognostic Impact of Genetic Characterization in the GIMEMA LAM99P Study for Newly Diagnosed Adult AML. Relevance of Combined Analysis of Conventional Karyotyping, FLT3 and NPM Mutational Status.
Authors: G. Saglio, Francesco Lo Coco, A. Cuneo, F. Pane, G. Rege Cambrin, D. Diverio, M. Mancini, N. Testoni, M. Vignetti, P. Fazi, S. Iacobelli, A. Bardi, B. Izzo, N. Bolli, R. La Starza, S. Amadori, F. Mandelli, P.G. Pelicci, C. Mecucci, B. Falini
Journal: Blood (2005)
HIV Triggers Interleukin 21-Mediated Induction of Granzyme B-Secreting B Cells with Regulatory and Antiviral Potential
Authors: Christof Kaltenmeier, Ali Gawanbacht, Stefanie Lindner, Thamara Beyer, Georg Haerter, Beate Gruener, Peter Kern, Frank Kirchhoff, Hubert Schrezenmeier, Bernd Jahrsdörfer
Journal: Blood (2012)
The Heat Shock Protein 32 (Hsp32)/HO-1-Targeting Drug SMA-ZnPP and the Triterpenoid CDDO-Me Exert Synergistic Growth-Inhibitory Effects on TKI-Resistant Leukemic Cells in Ph+ CML
Authors: Karoline V. Gleixner, Harald Herrmann, Katharina Blatt, Winfried F Pickl, Marina Konopleva, Gahininath Y Bharate, Michael Andreeff, Hiroshi Maeda, Peter Valent
Journal: Blood (2011)
G-CSF Induces Expression of Both Hepatocyte Growth Factor (HGF) and Its Receptor (c-Met) in Human Hematopoietic Stem/Progenitor Cells and Mature Myeloid Cells - Novel Evidence That during Mobilization the HGF-c-Met Axis Counterbalances G-CSF-Induced Attenuation of the SDF-1-CXCR4 Axis.
Authors: Ali Jalili, Neeta Shirvaikar, Sara Ilnitsky, A. Robert Turner, Mariusz Z. Ratajczak, Anna Janowska-Wieczorek
Journal: Blood (2007)
Alterations in the Physiology of Multipotent Mesenchymal Stromal Cells from the Bone Marrow of Patients with Leukemia
Authors: Tamara Sorokina, Irina Shipounova, Alexey Bigildeev, Nataliya Petinati, Nina I. Drize, Anna Turkina, Ekaterina Chelysheva, Oleg Shukhov, Larisa A. Kuzmina, Elena N. Parovichnikova, Valeriy G Savchenko
Journal: Blood (2015)
Genome Wide SNP Analysis Reveals Frequent Uniparental Disomy (UPD) Due to Somatic Recombination in Acute Myeloid Leukemias.
Authors: Manoj Raghavan, Debra Lillington, Spyros Skoulakis, Silvana Debernardi, Tracy Chaplin, Nicola J. Foot, T. Andrew Lister, Bryan D. Young
Journal: Blood (2004)
CRISPR/Cas9-Mediated Genome Editing as a Therapeutic Approach for Leber Congenital Amaurosis 10
Authors: Guo-Xiang Ruan, Elizabeth Barry, Dan Yu, Michael Lukason, Seng H. Cheng, Abraham Scaria
Journal: Molecular Therapy (2017)

As the most common subtype of Leber congenital amaurosis (LCA), LCA10 is a severe retinal dystrophy caused by mutations in the CEP290 gene. The most frequent mutation found in patients with LCA10 is a deep intronic mutation in CEP290 that generates a cryptic splice donor site. The large size of the CEP290 gene prevents its use in adeno-associated virus (AAV)-mediated gene augmentation therapy. Here, we show that targeted genomic deletion using the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system represents a promising therapeutic approach for the treatment of patients with LCA10 bearing the CEP290 splice mutation. We generated a cellular model of LCA10 by introducing the CEP290 splice mutation into 293FT cells and we showed that guide RNA pairs coupled with SpCas9 were highly efficient at removing the intronic splice mutation and restoring the expression of wild-type CEP290. In addition, we demonstrated that a dual AAV system could effectively delete an intronic fragment of the Cep290 gene in the mouse retina. To minimize the immune response to prolonged expression of SpCas9, we developed a self-limiting CRISPR/Cas9 system that minimizes the duration of SpCas9 expression. These results support further studies to determine the therapeutic potential of CRISPR/Cas9-based strategies for the treatment of patients with LCA10.
Improve Quality, Control Spending, Maintain Access — Can the Merit-Based Incentive Payment System Deliver?
Authors: Eric C. Schneider, Cornelia J. Hall
Journal: New England Journal of Medicine (2017)

Medicare's Merit-Based Incentive Payment System will adjust payments for performance on quality measures, clinical practice improvement activities, resource use, and IT use. But by allowing clinicians to customize their compliance, it may invite unforeseen effects.
Titin (ITN) mutations in dilated cardiomyopathy: Evidence for cardiac but not skeletal muscle haploinsufficiency in a I-Band truncation mutation and further genetic (Allelic and non-allelic) heterogeneity
Authors: B Gerull, S Sasse-Klaassen, J Atherton, S Probst, M McNabb, M Frenneaux, H Granzier, S Labeit, L Thierfelder
Journal: Circulation (2003)
A new year hangover the NHS can’t shake off
Authors: Nigel Edwards
Journal: BMJ (2017)

Brexit has transformed UK politics. Where does it leave the NHS?



Brexit means uncertainty and a high level of confusion for the United Kingdom and the NHS, as Martin McKee has described in a BMJ blog.1 Much has been written about Brexit’s effect on the many clinicians and other staff from the European Union who make a vital contribution to health services and to social care. Those who are here now don’t know whether they will be able to remain, while those who are needed to fill gaps in the workforce have seen their potential salary devalued by over 15%, with the fall in the value of sterling. Some of the rhetoric heard from prominent politicians has not helped. All this comes at a time of serious staff shortages …
Chemosensitization of Diffuse Large B Cell Lymphoma by Demethylating Nucleoside Analogues
Authors: Thomas Clozel, ShaoNing Yang, Matthias Kormaksson, Rebecca Elstrom, Aparna Vasanthakumar, Sarah Brennan, Biljana Culjkovic, Michael Leser, Peter Martin, Katherine LB Borden, Y. Lynn Wang, Shuhua Cheng, Wayne Tam, Rita Shaknovich, Amy Chadburn, Lucy Godley, John P. Leonard, Ari Melnick, Leandro Cerchietti
Journal: Blood (2011)
Combination of the vascular disrupting agent DMXAA (AS1404) with bevacizumab and paclitaxel produces synergistic antitumor activity in lung cancer xenografts
Authors: Hakim Djeha, Kirti Shah, Grainne McGeever, Donna Dobinson, Colin Green
Journal: Cancer Research (2007)

4642   The anti-VEGF monoclonal antibody, bevacizumab, has been approved for use alongside chemotherapy in colorectal, non-small cell lung, and breast cancers, highlighting the therapeutic value of combining anti-angiogenic therapies with cytotoxic drugs. Vascular disrupting agents (VDAs) are a distinct approach to the targeting of tumor vasculature based on disruption of established tumor blood vessels. VDAs are also most effective in combination settings: the small-molecule VDA DMXAA (AS1404) recently produced a substantial survival benefit when combined with carboplatin and paclitaxel in a phase II trial in non-small cell lung cancer. We have previously shown that combining the two anti-vascular approaches of anti-angiogenesis and a VDA produces synergistic anti-cancer effects. We now extend these studies to evaluate a triple combination of DMXAA with bevacizumab and the cytotoxic paclitaxel.  Xenografts were established in nude mice following inoculation with the A549 (NSCLC) cell line and allowed to grow to approximately 100 mm 3 . Mice (11 per group) were treated with DMXAA (21 mg/kg twice weekly in weeks 1 and 4) or bevacizumab (5 mg/kg, twice weekly for 4 weeks) or paclitaxel (5 mg/kg twice weekly in weeks 1 and 4) or the triple combination (21 mg/kg, 5 mg/kg and 5 mg/kg given as above). Control mice were untreated. Effects on growth were measured and outcomes were classed as complete responses (no tumor detected for 2 weeks); partial responses (>50% reduction in volume over 2 weeks); progressive disease (>50% increase in volume) or stable disease (all others).  The triple combination of DMXAA, bevacizumab and paclitaxel produced sustained tumor regression (71-day median time to return to baseline volume). None of the agents alone caused tumor regression. The combination group showed more than 3 months9 growth delay compared to untreated controls. Paclitaxel alone had no effect on tumor growth, while bevacizumab or DMXAA alone each produced modest but statistically significant reductions in tumor growth rate compared to untreated controls (26 and 35-day delays, respectively).  In outcome terms, the triple combination produced 2 complete responses, 4 partial responses and 4 cases of stable disease. There were no responses in the single agent or untreated groups. The combination regimen increased time to tumor progression by 78 days vs untreated controls.  When compared with previous data for DMXAA plus bevacizumab or DMXAA plus paclitaxel combinations, the triple combination was superior in all respects and was not associated with greater toxicity.  In conclusion, we have shown that a triple therapy regime targeting established vasculature (with the VDA, DMXAA), neovasculature (with the anti-VEGF antibody, bevacizumab) and tumor cells directly (with the cytotoxic, paclitaxel) has significant promise and warrants evaluation in clinical trials.
Impact of Cytogenetics and New Molecular Markers On the Achievement of Complete Remission in Patients with Primary Acute Myeloid Leukemia. On Behalf of CETLAM Cooperative Group. Spain.
Authors: Salut Brunet, Mar Tormo, Jordi Esteve, Josep M. Ribera, Montserrat Hoyos, Josep F. Nomdedeu, Rafael Duarte, Andreu Llorente, Ramon Guardia, M. Paz Queipo de Llano, Joan Besalduch, Inmaculada Heras, Joan Bargay, Carmen Pedro, Josep M. Marti, Javier Bueno, Pio Torres, Dolores Hernandez, Jose Gonzalez, Antoni Garcia, Llorenç Font, Montserrat Arnan, Albert Oriol, David Gallardo, Rosa Goterris, Emili Montserrat, Jorge Sierra
Journal: Blood (2009)